HIV prevention with PrEP for people on opioid therapy
Part of Immune system & allergy, Infections clinical trials.
This trial tests if daily PrEP medication can help prevent HIV in people receiving opioid replacement therapy. You must be HIV-negative and regularly attend your opioid treatment program to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are HIV negative.
- You have behaviors that might expose you to HIV, as decided by your doctor.
- You have been going to your opioid treatment program at least 3 days a week for the past 2 weeks.
- You are willing to come back for follow-up visits.
- Your kidneys work well enough (creatine clearance of 30 or higher) and you don't take any medicines that conflict with PrEP.
- You haven't taken any PrEP in the last 24 hours, and you are not currently needing HIV emergency prevention (PEP).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how to better support HIV prevention for people who inject drugs and are newly starting PrEP (medicine to prevent HIV). It focuses on people taking medication for opioid use disorder and who have mild thinking and memory problems, to help them stay safe and adhere to prevention.
This trial looks at how well a daily HIV-prevention pill (F/TAF) works in people who use drugs. The goal is to understand real-world effectiveness and help support people in staying HIV-negative.
This study tests whether a combination of buprenorphine (a medication for opioid addiction) and PrEP (a daily pill to prevent HIV) can help people who are leaving jail or prison stay healthy. It aims to reduce both opioid relapse and HIV risk during the transition back to the community.
This study tests how taking two tablets of a PrEP medication (F/TAF) at once affects healthy volunteers. It helps us understand the safety and how the body processes the drug.
This study follows adults who are at high risk of getting HIV while they take HIV prevention pills (PrEP). It aims to learn how well PrEP fits real-life use in people at risk and who may need extra care.
This study helps people who inject drugs start HIV prevention (PrEP) and medication for opioid use disorder (MOUD) faster. It may reduce HIV risk and improve access to treatment, while the study checks whether the “rapid access” approach works.
Hear when a new HIV (Human Immunodeficiency Virus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.